approach phase efficaci phase safeti
updat vertex triplet cystic fibrosi cf regimen thought
import highlight street potenti signific sales/earn power
next year prior histori launch monotherapi
doublet regimen variou cf mutat seem current opco
consensu expect year sales/earn growth moder strong
hetmin triplet launch coupl increas penetr current
approv indic due increas triplet efficaci could increas sales/earn
expect time-frame room upsid
would impli share price stay bullish
biggest push-back get investor cheap
success triplet cf launch price stock disagre
current trade large-cap price-to-earnings multipl would
argu consensu opco model moder triplet
launch pois outperform
model scenario triplet launch outcom base histori
three cf launch past seven year begin
kalydeco main take-away current consensu opco
expect gear around moder triplet launch possibl
low sale earn growth
success triplet launch hetmin patient popul
ww penetr vs current opco expect would increas
sales/earn expect consensu
assum increas penetr current approv indic like
homozyg due stronger benefit/risk profil triplet regimen
report efficaci phase demonstr
potenti superior efficaci doublet orkambi/symdeko without
increas safeti signal third scenario contempl strong hetmin launch
increas penetr current approv indic lead
increas sales/earn expect consensu
room upsid
key point make investor increas visibl triplet
approv impend safeti data would mean at-least one triplet
submit consensu sales/earn number could start rise triplet
launch earli stock rise anticip trend stock
demonstr previous see exhibit investor take note
year price histori
global biotechnolog
compani discov develop
seriou diseas
analyst certif import disclosur see disclosur
orkambi achiev patient penetr homozyg
symdeko tez/iva success approv get
homozyg penetr
slower expect eu launch orkambi franc
price
triplet late-stag clinic trial news flow
provid visibl pipelin beyond cf
rate vertex outperform price target
compani posit deliv strong sale earn
growth next five year potenti even
greater growth near- tezacaftor/ivacaftor mid-term triplet
therapi homozyg cf patient
product launch outperform opex reach steadi state
could begin upsid stori believ
orkambi/symdeko reimburs approv addit ex-
us countri uk/france/etc us approv symdeko age
year kalydeco infant month
safeti
updat one/day triplet updat next-gen
pipelin project phase scd beta-th phase
ind fsg candid
submit nda triplet regimen
vertex secur broad reimburs cf franchis ex-u
rapidli expect
symdeko sale ramp faster expect
triple-combin regimen tez/iva plu anoth corrector
approv market hetmin popul
disclos addit pipelin opportun
failur secur cf regulatori approvals/reimburs ex-u
lower expect uptak orkambi/symdeko
compet regimen other abbvie/galapgo
approv earlier expect take signific market share
pt util composit valuat methodolog biotech compani util forward p/
 multipl npv adj estim earn sinc biotech high-growth/high-expect sector aim rank target
compani base qualiti sale and/or earn growth vs peer group peer index nbi expect
earn growth next three five year well expect higher termin multipl due
perceiv greater certainti qualiti sales/earn growth appli discount rate vs peer group average
slow cf sale disappoint commerci launch penetr tezacaftor/ivacaftor pipelin failur triplet regimen and/
regulatori non-approv kalydeco label extens
correct previou note publish attach end note exhibit bull case
penetr correct reflect base case estim
symdeko recent launch doublet see bullish launch
thought survey january/februari share price
valuat past year deriv function kaldeco ivacaftor
approv januari orkambi lumacaftor/ivacaftor approv juli
kalydeco launch one rapid us ex-u territori
orkambi launch modest one especi rel kalydeco
orkambi receiv label expans addit patient septemb
ex-u set differ even dramat
kalydeco potenti address patient ww saw
penetr initi adult cf mutat patient popul eu
orkambi sale ex-u sluggish due pauciti reimburs
approv variou eu rest-of-world row countri drug
potenti approv us quarter launch believ
eu row situat potenti penetr respect
reimburs contract negoti ex-u countri
orkambi increasingli symdeko near approv variou ex-u
countri main overhang share price recent
believ uk franc two main hold-out ex-u orkambi/symdeko
approv symdeko tezacaftor/ivacaftor ivacaftor doublet regimen
favor benefit/risk profil orkambi significantli ad vrtx total cf
patient popul
expect effect moder driven mostli ex-u countri
assum triplet substitut
per vrtx indic earn call potenti
cf patient treat current approv cf medic on-drug
us patient on-drug believ
fairli obviou kalydeco orkambi/symdeko launch near-term
perform driven rapid us uptak perform year post-launch
driven ex-u market uptak follow usual lengthier reimburs discuss
assum triplet substitut
believ strong launch kalydeco sub-optim launch orkambi
coupl better-than-orkambi launch symdeko creat dichotomi
consensu expect potenti triplet therapi continu vrtx
current bloomberg consensu expect vrtx year sales/earn
fairli moder believ
consensu revenu expect vs opco
approxim kalydeco orkambi/symdeko vs opco
rest come triplet revenu peopl one mutat
suggest consensu revenu hetmin
cf patient popul approxim penetr ww assum
earli launch
consensu revenu expect vs opco
approxim kalydeco orkambi/symdeko vs
opco rest come triplet revenu peopl one
mutat one minim function mutat hetmin cf patient
suggest consensu revenu hetmin cf
cf patient popul approxim penetr ww assum
earli launch
current opco estim sales/earn in-lin consensu
expect see revenu
earn opco model ep vs
earn opco model ep vs
opco consensu non-gaap earn expect like due
model higher opex spend
assumpt start pay cash tax rate
share outstand go forward
assum triplet substitut kalydeco orkambi/symdeko
residu function etc similar price level
assum triplet therapi approv variou geographi
variou younger cf popul adolesc younger triplet
substitut also occur pace similar price point
model triplet penetr hetmin patient
sinc opco in-line consensu sales/earn
current expect believ conserv triplet therapi vrtx
abil fiscal disciplin
scenario result sales/earn in-line consensu
sales/earn consensu expect
note current model scenario assum orkambi-lik
launch triplet hetmin regimen ww penetr
assum intermedi launch somewher kalydeco
orkambi/symdeko model consensu expect
assum ww hetmin penetr
assum scenario chang stronger triplet hetmin launch
opco sales/earn consensu
expect testament power gain access hetmin
patient current avail
scenario assum follow
assum triplet therapi hetmin cf patient popul
gain ww penetr like kalydeco
assum triplet therapi increas penetr homozyg
patient variou current approv genet mutat
assum scenario opco model would consensu
expect sales/earn
remind reader adjust opco opex tax assumpt
consensu adjust consensu level would lead
opco earn consensu expect
statement revenu royalti revenu collabor total product royalti research develop sale gener administr restructur expenses- intang asset impair charges- total cost expens incom loss oper interest incom net- interest expens incom expens incom loss provis benefit incom tax provis benefit incom provis non-cash taxes- net incom loss net incom loss attribut vertex dilut share outstand
